<DOC>
	<DOCNO>NCT01968044</DOCNO>
	<brief_summary>Therapuetic option limit Type 2 Diabetes Mellitus ( T2DM ) pateints renal impairment . This clinical study ass safety efficacy DPP-4 inhibitor gemigliptin patient type 2 DM moderate severe renal impairment long-term peirod ( 52 week ) .</brief_summary>
	<brief_title>A Phase IIIb Study Evaluate Safety Efficacy Gemigliptin Type 2 Diabetes Mellitus Patients With Moderate Severe Renal Impairment ( GUARD Study )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Patients Type 2 Diabetes Mellitus Patients moderate severe renal insufficiency All patient give write informed consent Has type 1 diabetes mellitus history ketoacidosis Is dialysis likely need dialysis study Has active liver disease</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>renal impairment</keyword>
</DOC>